Further to DrugAlert volume 890, HPS Pharmacies wishes to provide an update on the availability of morphine oral solution. While Ordine® Oral Solution was discontinued by Mundipharma in 2023, Arrotex Pharmaceuticals has now announced that it will be taking over the sponsorship of the Ordine® range.

Arrotex anticipates that supplies of all strengths of Ordine® Oral Solution will resume by late August 2024. In the meantime, several overseas registered morphine oral solution products remain approved for supply under Section 19A of the Therapeutic Goods Act 1989.

Products approved under Section 19A include:

  • Morphine sulfate 2mg/mL oral solution (Hikma)
  • Morphine sulfate 10mg/5mL oral solution (Martindale Pharma)
    • Warning – this product contains ethanol (0.4mL per 5mL) and sucrose (2.25g per 5mL).
  • Morphini HCl Streuli (morphine hydrochloride) 10mg/mL oral drops (Switzerland)
    • Warning – this product is not labelled in English. Additional care is required when storing and dispensing this medicine. Appropriate auxiliary labels should be provided. Health professionals should refer to the Australian product information for dosing information.
    • Warning – this product contains alcohol (1.2% v/v).

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Mundipharma on 1800 188 009 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates